Tumor and genetic features that separate platinum‑resistant ovarian cancer patients from those progression‑free at five years

Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy.

This project will test whether clinical, tissue, and genomic features can separate ovarian cancer patients who do not respond to first‑line platinum chemotherapy from those who stay progression‑free for five years.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 55 (estimated)
• Ages: 18 Years and up
• Sex: Female
• Sponsor: Centre Jean Perrin (other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Clermont-Ferrand, PUY DE DOME)
• Trial ID: NCT07361471 on ClinicalTrials.gov

What this trial studies

Using the CONSORE database, the ORTRAI cohort was assembled at Centre Jean Perrin to compare patients who progressed on first‑line platinum therapy with those progression‑free five years after treatment. Clinical records, biological data, and tumor histology will be collected and compared with literature cohorts to confirm representativeness. Immunohistochemistry and molecular analyses will be performed on available FFPE tumor blocks to identify distinguishing genomic and tissue features. Integrative analysis will seek markers associated with platinum resistance or long‑term durable response.

Who should consider this trial

Good fit: Adults treated at Centre Jean Perrin for ovarian cancer who received first‑line platinum‑based chemotherapy and either progressed during that first line or remained progression‑free five years later, who have social security coverage, signed genetic consent, and have an available FFPE tumor block.

Not a fit: Minors, pregnant patients, those under guardianship, patients without available tumor tissue, those who refuse data collection, patients with AME, or individuals not treated at Centre Jean Perrin are not eligible and are unlikely to benefit from this project.

Why it matters

Potential benefit: If successful, this work could identify markers to predict who will benefit from platinum chemotherapy and support more personalized treatment decisions.

How similar studies have performed: Prior studies have reported molecular and histologic factors linked to platinum resistance in ovarian cancer, but no single predictive marker is yet universally reliable, so this work builds on suggestive but incomplete evidence.

Eligibility criteria

Inclusion Criteria:

* Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment.
* Corresponding to one of the two groups below:

  * Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy.
  * Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment
* Affiliation to a social security scheme
* Patient who signed the genetic consent form

Exclusion Criteria:

* Minor patient
* Pregnant patient
* Patient under guardianship or conservatorship
* Patients who object to the collection of their medical/paramedical data
* Patient for whom the center does not have biological material for genomic analysis (FFPE block)
* Patient under administrative, judicial decision or AME (State Medical Aid)

Where this trial is running

Clermont-Ferrand, PUY DE DOME

• Centre Jean Perrin — Clermont-Ferrand, PUY DE DOME, France (RECRUITING)

Study contacts

• Principal investigator: Tressie HERRMANN, MD — Centre Jean Perrin
• Study coordinator: Judith PASSILDAS JAHANMOHAN, PhD

Conditions: Ovarian Cancer, ovarian cancer, long responder